BR9915004A - Benzoilpiridazinas - Google Patents

Benzoilpiridazinas

Info

Publication number
BR9915004A
BR9915004A BR9915004-2A BR9915004A BR9915004A BR 9915004 A BR9915004 A BR 9915004A BR 9915004 A BR9915004 A BR 9915004A BR 9915004 A BR9915004 A BR 9915004A
Authority
BR
Brazil
Prior art keywords
derivatives
benzoylpyridazines
benzoilpyridazines
phosphorodiesterase
cachexia
Prior art date
Application number
BR9915004-2A
Other languages
English (en)
Inventor
Rochus Jonas
Michael Wolf
Franz-Werner Kruxen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9915004A publication Critical patent/BR9915004A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

Patente de Invenção: "BENZOILPIRIDAZINAS". A invençãorefere-se a derivados de benzoil piridazina de fórmula I onde R^ 1^,R^ 2^, R^ 3^ e Q têm o significado definido na reivindicação 1.Tais derivados têm um efeito inibidor de fosforodiesterase IV epodem ser usados em tratamento de osteoporose, tumores,caquexia, arteriosclerose, artrite reumatóide, esclerose múltipla,diabetes mellitus, processos inflamatórios, alergias, asma, doençasauto-imune e AIDS.
BR9915004-2A 1998-11-04 1999-10-23 Benzoilpiridazinas BR9915004A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19850701A DE19850701A1 (de) 1998-11-04 1998-11-04 Benzoylpyridazine
PCT/EP1999/008047 WO2000026201A1 (de) 1998-11-04 1999-10-23 Benzoylpyridazine

Publications (1)

Publication Number Publication Date
BR9915004A true BR9915004A (pt) 2001-11-13

Family

ID=7886577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915004-2A BR9915004A (pt) 1998-11-04 1999-10-23 Benzoilpiridazinas

Country Status (24)

Country Link
US (1) US6376493B1 (pt)
EP (1) EP1124809B1 (pt)
JP (1) JP4354652B2 (pt)
KR (1) KR20010075636A (pt)
CN (1) CN1142153C (pt)
AR (1) AR021068A1 (pt)
AT (1) ATE262513T1 (pt)
AU (1) AU759328B2 (pt)
BR (1) BR9915004A (pt)
CA (1) CA2349232A1 (pt)
CZ (1) CZ20011551A3 (pt)
DE (2) DE19850701A1 (pt)
DK (1) DK1124809T3 (pt)
ES (1) ES2214891T3 (pt)
HU (1) HUP0104033A3 (pt)
ID (1) ID28816A (pt)
NO (1) NO20012188L (pt)
PL (1) PL346909A1 (pt)
PT (1) PT1124809E (pt)
SI (1) SI1124809T1 (pt)
SK (1) SK5782001A3 (pt)
TW (1) TW458970B (pt)
WO (1) WO2000026201A1 (pt)
ZA (1) ZA200104541B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19915364A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Verwendung von Arylalkanoylpyridazinen
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US20050070529A1 (en) * 2001-02-12 2005-03-31 Merk Pantent Gmbh Use of type 4 phosphodiesterase inhibitors in myocardial diseases
ES2268157T3 (es) * 2001-11-05 2007-03-16 Merck Patent Gmbh Hidrazono-malonitrilos.
KR100866286B1 (ko) * 2001-11-29 2008-10-31 씨제이제일제당 (주) 신규한 카테콜 히드라지드 유도체 및 그의 제조방법
KR100508156B1 (ko) * 2002-11-29 2005-08-17 씨제이 주식회사 신규한 캐테콜 히드라자이드 유도체
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN113264899B (zh) * 2021-04-09 2022-06-14 台州学院 一种1，3，5-噁二嗪类化合物及其制备和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2139307A1 (en) 1992-07-01 1994-01-20 Donald W. Combs 1-arylsulphonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines
DE19514568A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine

Also Published As

Publication number Publication date
DE59908968D1 (de) 2004-04-29
CZ20011551A3 (cs) 2001-08-15
HUP0104033A2 (hu) 2002-05-29
AR021068A1 (es) 2002-06-12
JP4354652B2 (ja) 2009-10-28
EP1124809B1 (de) 2004-03-24
SK5782001A3 (en) 2001-11-06
ZA200104541B (en) 2002-09-02
CN1142153C (zh) 2004-03-17
KR20010075636A (ko) 2001-08-09
ID28816A (id) 2001-07-05
WO2000026201A1 (de) 2000-05-11
PT1124809E (pt) 2004-07-30
NO20012188D0 (no) 2001-05-03
NO20012188L (no) 2001-05-03
PL346909A1 (en) 2002-03-11
US6376493B1 (en) 2002-04-23
CN1324350A (zh) 2001-11-28
DE19850701A1 (de) 2000-05-11
TW458970B (en) 2001-10-11
SI1124809T1 (en) 2004-06-30
CA2349232A1 (en) 2000-05-11
ATE262513T1 (de) 2004-04-15
AU759328B2 (en) 2003-04-10
AU6342399A (en) 2000-05-22
JP2002528536A (ja) 2002-09-03
HUP0104033A3 (en) 2002-08-28
DK1124809T3 (da) 2004-07-19
ES2214891T3 (es) 2004-09-16
EP1124809A1 (de) 2001-08-22

Similar Documents

Publication Publication Date Title
BR9915004A (pt) Benzoilpiridazinas
TR200102967T2 (tr) Substitüsyonlu azollar
CA2456127A1 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
BR0311343A (pt) Derivados de piridazina
MXPA04004263A (es) Hidrazono-malonitrilos.
NZ335992A (en) Substituted pyrimidinone and pyridone compounds and methods of use
HK1051691A1 (en) Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition
AU2002316459A1 (en) Methods of treating cytokine mediated diseases
NO20030895L (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
BR9913532A (pt) Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase
WO2000044709A3 (en) ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
ATE253062T1 (de) 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
CA2226256A1 (en) New thrombin inhibitors, their preparation and use
DK0944616T3 (da) Bicykliske arylcarboxamider og deres terapeutiske anvendelse
CA2443285A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
AP2000001992A0 (en) Succinamide inhibitors of inteleukin-1B converting enzyme.
CA2312431A1 (en) New compounds
DK0980374T3 (da) Phosphodiesterase 4-inhiberende diazepinoindoloner.
IL143384A0 (en) New amidino derivatives and their use as thrombin inhibitors
DE69610978D1 (de) 4-substituierte-3-peptidyl-azetidin-2-on-derivate als cystein-proteinase inhibitoren
HK1053121A1 (en) New amidino derivatives and their use as thrombin inhibitors
GB9923710D0 (en) Chemical compounds
HUP0002304A2 (hu) Állatok májából kivonható fehérjék alkalmazása tumor nekrózis faktor túltermelődéssel járó kóros állapotok kezelésére használható gyógyászati készítmények előállítására

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.